相似文献
1
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
Alzheimers Dement. 2017 May;13(5):561-571. doi: 10.1016/j.jalz.2016.10.006. Epub 2016 Dec 5.
2
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13.
3
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001.
4
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22.
5
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7.
6
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2.
7
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.
8
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008.
9
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2015 Jul;11(7):730-3. doi: 10.1016/j.jalz.2015.05.007.
10
Integrating ADNI results into Alzheimer's disease drug development programs.
Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5.
引用本文的文献
1
Streamline Density Normalization: A Robust Approach to Mitigate Bundle Variability in Multi-Site Diffusion MRI.
bioRxiv. 2025 Aug 22:2025.08.18.670965. doi: 10.1101/2025.08.18.670965.
2
Unraveling Normal Anatomy via Fluid-Driven Anomaly Randomization.
Proc IEEE Comput Soc Conf Comput Vis Pattern Recognit. 2025 Jun;2025:10455-10465. doi: 10.1109/cvpr52734.2025.00978. Epub 2025 Aug 13.
3
Caudal and Thalamic Segregation in White Matter Brain Network Communities in Alzheimer's Disease Population.
IEEE EMBS Int Conf Biomed Health Inform. 2024 Nov;2024. doi: 10.1109/bhi62660.2024.10913835. Epub 2025 Mar 17.
4
Precision brain morphometry using cluster scanning.
Imaging Neurosci (Camb). 2024 May 20;2. doi: 10.1162/imag_a_00175. eCollection 2024.
5
Cortical and subcortical structural alterations in obsessive-compulsive disorder: relationships between morphology and clinical profiles in the Global OCD study.
medRxiv. 2025 Jul 23:2025.07.23.25332068. doi: 10.1101/2025.07.23.25332068.
6
Neurite Degradation Mediates the Effect of Amyloid Deposition on Global Cognition in Asymptomatic Older Adults.
medRxiv. 2025 Jul 23:2025.07.23.25332087. doi: 10.1101/2025.07.23.25332087.
7
miR-423-5p and miR-92a-3p in Alzheimer's disease: relationship with pathology and cognition.
Front Aging Neurosci. 2025 Jul 22;17:1637368. doi: 10.3389/fnagi.2025.1637368. eCollection 2025.
8
Whole-brain functional connectivity predicts regional tau PET in preclinical Alzheimer's disease.
Brain Commun. 2025 Jul 15;7(4):fcaf274. doi: 10.1093/braincomms/fcaf274. eCollection 2025.
9
Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer's disease.
Alzheimers Dement. 2025 Jul;21(7):e70511. doi: 10.1002/alz.70511.
10
Age- and Sex-Specific Cerebral Blood Flow Atlases for Healthy Brain Across the Lifespan.
Sci Data. 2025 Jul 9;12(1):1169. doi: 10.1038/s41597-025-05406-w.
本文引用的文献
1
2016 Alzheimer's disease facts and figures.
Alzheimers Dement. 2016 Apr;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001.
2
PET Imaging of Tau Deposition in the Aging Human Brain.
Neuron. 2016 Mar 2;89(5):971-982. doi: 10.1016/j.neuron.2016.01.028.
3
Incidence of Dementia over Three Decades in the Framingham Heart Study.
N Engl J Med. 2016 Feb 11;374(6):523-32. doi: 10.1056/NEJMoa1504327.
4
Suspected non-Alzheimer disease pathophysiology--concept and controversy.
Nat Rev Neurol. 2016 Feb;12(2):117-24. doi: 10.1038/nrneurol.2015.251. Epub 2016 Jan 18.
5
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.
Alzheimers Dement. 2016 May;12(5):517-26. doi: 10.1016/j.jalz.2015.09.009. Epub 2015 Nov 10.
6
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Brain. 2015 Nov;138(Pt 11):3373-85. doi: 10.1093/brain/awv267. Epub 2015 Sep 15.
7
GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP.
Brain. 2015 Oct;138(Pt 10):3076-88. doi: 10.1093/brain/awv231. Epub 2015 Aug 11.
8
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Alzheimers Dement. 2016 Feb;12(2):110-120. doi: 10.1016/j.jalz.2015.06.1893. Epub 2015 Aug 1.
9
Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.
Lancet Neurol. 2015 Sep;14(9):926-944. doi: 10.1016/S1474-4422(15)00153-2. Epub 2015 Jul 23.
10
Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
Alzheimers Dement. 2016 Jan;12(1):55-9. doi: 10.1016/j.jalz.2015.06.1890. Epub 2015 Jul 21.
Zotero 插件